Theriva Biologics
TOVX
32 hedge funds and large institutions have $3.18M invested in Theriva Biologics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 9 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0.01% less ownership
Funds ownership: 0.04% → 0.03% (-0.01%)
2% less capital invested
Capital invested by funds: $3.24M → $3.18M (-$56K)
3% less funds holding
Funds holding: 33 → 32 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$76.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.4K |
| 3 |
Millennium Management
New York
|
+$36.6K |
| 4 |
HF
HRT Financial
New York
|
+$27.8K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$24.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
-$299K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$76K |
| 3 |
MP
MSD Partners
New York
|
-$63.4K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$20K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$13.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWM
26
Axxcess Wealth Management
Carlsbad,
California
| $3K | +$2.73K | +40 | New |
|
27
Morgan Stanley
New York
| $1K | -$4.97K | -73 | -87% |
|
|
28
Truist Financial
Charlotte,
North Carolina
| – | -$299K | -4,400 | Closed |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$76K | -1,112 | Closed |
|
|
BCM
30
Bridgeway Capital Management
Houston,
Texas
| – | -$20K | -297 | Closed |
|
|
SCM
31
Sterneck Capital Management
Kansas City,
Missouri
| – | -$7K | -100 | Closed |
|
|
BSW
32
Buckingham Strategic Wealth
Clayton,
Missouri
| – | -$5K | -70 | Closed |
|
33
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$3 | -42 | Closed |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2.73K | -40 | Closed |
|
35
Bank of America
Charlotte,
North Carolina
| – | -$68 | -1 | Closed |
|
36
Fidelity Investments
Boston,
Massachusetts
| – | +$68 | +1 | New |
|
TOVX Hedge Fund Activity: Q1 2022 in Review
32 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2022, worth a combined $3.18M — down 1.7% from $3.24M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TOVX and 8 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.
The largest buyer was Jane Street, opening a new position worth an estimated $76.8K. The largest seller was Truist Financial, exiting entirely with an estimated $299K sold.
- 32 institutional investors held Theriva Biologics (TOVX) as of Q1 2022, down from 33 in Q4 2021.
- Funds reported $3.18M of Theriva Biologics stock for Q1 2022, down 1.7% quarter-over-quarter.
- 8 funds opened new Theriva Biologics positions in Q1 2022 and 9 closed out, a net change of -1 holder.
- The largest Theriva Biologics buyer in Q1 2022 was Jane Street, an estimated $76.8K added.
- The largest Theriva Biologics seller in Q1 2022 was Truist Financial, an estimated $299K sold.
Based on aggregated 13F filings for Q1 2022.